Quick answer: latest quarter results, by ticker or company name

Reported Q: Q3 2024 Rev YoY: N/A EPS YoY: +118.4% Move: -0.34%

Genor Biopharma Holdings

6998.HK

HKD2.97 -0.34%

Exchange HKSE Sector Healthcare Industry Biotechnology

Q3 2024

Published: Sep 30, 2024

Company Status Snapshot

Fast view of the latest quarter outcome for 6998.HK

Reported

Report Date

Sep 30, 2024

Quarter Q3 2024

Revenue

95.88M

YoY: N/A

EPS

0.07

YoY: +118.4%

Market Move

-0.34%

Previous quarter: N/A

Follow this company to get upcoming quarter alerts automatically.

Earnings Highlights

Revenue of $95.88M up 0% year-over-year
EPS of $0.07 increased by 118.4% from previous year
Gross margin of 99.5%
Net income of 37.21M
"Not available in the provided transcript dataset." - N/A

6998.HK

Company 6998.HK

Period Q3 2024

Currency CNY

Report Type Quarterly Earnings

Generated Feb 11, 2026

Executive Summary

Genor Biopharma reported QQ3 2024 results with a pronounced QoQ revenue increase and an exceptionally high gross margin, underpinned by a positive bottom line. Revenue reached 95.88 million CNY, up 1,225.22% QoQ from Q2 2024, while gross profit stood at 95.38 million CNY for a gross margin of 99.48%. Operating income was 28.76 million CNY, and net income was 37.21 million CNY, delivering an EPS of 0.0719 CNY. The quarter also featured a favorable pre-tax margin (48.20%) and an after-tax margin of 38.80%. Management commentary is not provided in the transcript feed, but the earnings metrics imply a mix of recurring, high-margin activities and possible one-time or milestone-driven revenue recognition.

Key Performance Indicators

Revenue

Stable

95.88M

QoQ: 1 225.22% | YoY: N/A

Gross Profit

Stable

95.38M

99.48% margin

QoQ: 1 250.95% | YoY: N/A

Operating Income

Increasing

28.76M

QoQ: 144.22% | YoY: 117.47%

Net Income

Increasing

37.21M

QoQ: 159.20% | YoY: 118.61%

EPS

Increasing

0.07

QoQ: 159.92% | YoY: 118.44%

Revenue Trend

Margin Analysis

Financial Highlights

Revenue: 95.88m CNY, QoQ +1,225.22% (YoY not disclosed); Gross Profit: 95.38m CNY, Gross Margin: 99.48%; EBITDA: 29.82m CNY; Operating Income: 28.76m CNY, Operating Margin: 29.98%; Net Income: 37.21m CNY, Net Margin: 38.80%; EPS: 0.0719 CNY; R&D: 46.55m CNY; SG&A: 16.58m CNY; Other Expenses: 3.49m CNY; Tax: 9.56m CNY; Net Cash Position: ~1,058.79m CNY; Total Assets: ~1,289.73m CNY; Total Liabilities: ~138.05m CNY; Current Ratio: 8.74x; P/B: 0.67x; P/S: 8.04x; P/E: 5.18x.

Income Statement

Metric	Value	YoY Change	QoQ Change
Revenue	95.88M	N/A	1 225.22%
Gross Profit	95.38M	N/A	1 250.95%
Operating Income	28.76M	117.47%	144.22%
Net Income	37.21M	118.61%	159.20%
EPS	0.07	118.44%	159.92%

Key Financial Ratios

Gross Profit Margin

Excellent

99.50%

Gross profit margin is exceptional, indicating strong pricing power and operational efficiency

Operating Profit Margin

Excellent

30.00%

Operating margin is exceptional, indicating strong pricing power and operational efficiency

Net Profit Margin

Excellent

38.80%

Net profit margin is exceptional, indicating strong pricing power and operational efficiency

Return on Assets

Weak

2.88%

Return on assets suggests inefficient capital allocation

Return on Equity

Weak

3.23%

Return on equity suggests inefficient capital allocation

Current Ratio

Strong

8.74

Current ratio indicates excellent liquidity and financial flexibility

Debt to Equity

Conservative

0.00

Debt-to-equity shows conservative leverage and low financial risk

P/E Ratio

Value

5.18x

P/E ratio suggests potential undervaluation or stable earnings

Price to Book

Undervalued

0.67x

Trading below book value, potential value opportunity or distressed

Historical Earnings Comparison

Period	Revenue ($M)	EPS ($)	YoY Growth	Report
Q2 2025	16.12	-0.05	-66.4%	View
Q1 2025	16.12	-0.05	+122.8%	View
Q4 2024	95.88	0.07	+0.0%	View
Q3 2024	95.88	0.07	+0.0%	View

Genor Biopharma Holdings (6998.HK) Q3 2024 Earnings Report

Company Status Snapshot

Earnings Highlights

Executive Summary

Key Performance Indicators

Revenue Trend

Margin Analysis

Financial Highlights

Income Statement

Key Financial Ratios

Management Insights Available for Members

Peer Comparison Available for Members

Investment Outlook & SWOT Available for Members

Historical Earnings Comparison

More 6998.HK Quarterly Reports

6998.HK

6998.HK

6998.HK

Q3 2024 Reports in Healthcare Sector

Related Financial Data

Sector Analysis: Healthcare

6998.HK Full Profile

6998.HK Financial Statements

Earnings Calendar